And that posed a significant threat to Zimmer Biomet, which bills itself as a worldwide leader in hip and knee replacements. A report from trade publication Fierce Biotech last year said that the companyâ€™s hip and knee implants account for 60 percent of its revenue.   In September 2015, Price spearheaded a letter to Andy Slavitt, the acting administrator of CMS, asking that the regulation be delayed because it "represents a significant change to our healthcare delivery system which could have a negative impact on patient choice, access and quality. "  Campaign donation from company, 